Dak Gesundheit Tender

§ 130a paragraph 8 SGB V enables the health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be supplied at the expense of the statutory health insurance companies. With regard to the relevant legal regulations for the award of public contracts, a regular process of active substance-related, formal award procedures takes place according to the regulations of the 4th part of the GWB by the DAK-Gesundheit. DAK-Gesundheit intends to conclude drug discount contracts with as many interested pharmaceutical companies as possible until new drug discount contracts come into force for drugs to be specified by the bidder in Annex 2 to the contract for the above-mentioned active substance chlortalidone, ATC C03BA04. A discount agreement iRd approval model for the above-mentioned active ingredient occurs for the first time on 01.09. 2022 and ends on August 31, 2024. Irrespective of this, it ends automatically when the exclusive contract comes into force.